TICKERNERD
Menu
PGNYPGNYHealthcare · Healthcare Plans

PGNY Stock Forecast: Progyny, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$26
+0.54% on the day

The 12 Wall Street analysts covering Progyny, Inc. hold a median 12-month price target of $35 — +34.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 23 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.0B
Ticker Nerd rank
96 / 100
Median analyst target
$35
Analysts covering
12
Revenue$350.5M+5.3% y/y
Operating income$40.0M
Net income$28.1M
Free cash flow$44.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
+2.0%
YTD
+1.1%
1Y
+19.7%
From 52W high
−19.7%
From 52W low
+59.3%
$16
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PGNY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Progyny, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Issuance
93
Accruals
87
Value
83
Growth
78
Volatility
70
Momentum
66
Revisions
50
Size
35

Quality (94): The business earns solid, repeatable profits on what it owns.

Revisions (50): Analysts have, on balance, been cutting their forecasts.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PGNY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PGNY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26PGNYHigh $40Median $35Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $30Median $35High $40

The green dot is the last close — the median target sits +34.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
8 Sept 2026CitizensMaintainsMarket Outperform$31 → $33
21 Aug 2026JP MorganMaintainsNeutral$27 → $30
21 Aug 2026JP MorganMaintainsNeutral—
20 Aug 2026Wells FargoInitiatesOverweight$37
20 Aug 2026Wells FargoInitiatesOverweight—
13 Aug 2026Truist SecuritiesMaintainsBuy—
13 Aug 2026Truist SecuritiesMaintainsBuy$33 → $36
12 Aug 2026BarclaysMaintainsEqual-Weight—
12 Aug 2026BarclaysMaintainsEqual-Weight$34 → $30
28 July 2026BarclaysDowngradeEqual-Weight$27 → $34
28 July 2026BarclaysDowngradeEqual-Weight—
24 July 2026BTIGMaintainsBuy$30 → $40
24 July 2026BTIGMaintainsBuy—
21 July 2026Canaccord GenuityMaintainsBuy—
21 July 2026Canaccord GenuityMaintainsBuy$30 → $36
13 July 2026KeybancMaintainsOverweight—
13 July 2026KeybancMaintainsOverweight$30 → $35
22 June 2026Truist SecuritiesMaintainsBuy—
2 June 2026B of A SecuritiesMaintainsBuy—
19 May 2026Canaccord GenuityUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PGNY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PGNY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Progyny, Inc. returned +19.7% against +17.3% for the S&P 500, dividends included.

PGNY vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26PGNYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PGNY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.3%
Analysts raising
8
Analysts cutting
0
Fundamentals

Progyny, Inc. (PGNY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
28.1×

Cheaper than 26% of US stocks

Price / sales
1.5×

Cheaper than 58% of US stocks

Price / book
4.4×

Cheaper than 23% of US stocks

EV / EBITDA
14.1×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
5.3%

Higher than 40% of US stocks

Earnings growth (YoY)
63.9%

Higher than 78% of US stocks

Gross margin
25.5%

Higher than 28% of US stocks

Operating margin
11.4%

Higher than 66% of US stocks

Net margin
6.0%

Higher than 62% of US stocks

Returns & dividend
Return on equity
16.2%

Higher than 76% of US stocks

Return on assets
10.1%

Higher than 92% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Progyny, Inc. (PGNY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Progyny, Inc. has a market value of $2.0B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 5.3% year on year.

  • Net income over the same four quarters: $78.6M, a 6.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.92.

  • Free cash flow in the twelve months to 30 June 2026: $178.4M.

  • Progyny, Inc. spent $230.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 77.4M.

  • Trailing P/E: 28.1×; forward P/E: 11.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Progyny, Inc. employs 835 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

PGNY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
PGNYProgyny, Inc.$2.0B
96
CLOVClover Health Investments Corp.$2.4B
68
ALHCAlignment Healthcare, Inc.$1.6B
65
OSCROscar Health, Inc.$9.1B
89
MOHMolina Healthcare, Inc.$9.7B
34
CNCCentene Corp.$30.5B
94
URGNUroGen Pharma Ltd.*$2.0B
79

* Nearest Healthcare names by size — few healthcare plans companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Progyny, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PGNY news & analysis

PGNY vs. CRL: Which Stock Is the Better Value Option?

Zacks Investment Research · 18 Sept 2026neutral

Zacks Investment Research compares Progyny (PGNY) and Charles River Laboratories (CRL) as potential value options within the Medical Services sector. The piece poses the question of which of these two stocks offers investors the better value opportunity at this time.

Why it matters — The article provides a value-focused comparison that PGNY watchers could use to gauge how the company is positioned relative to a peer in the same sector.

Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027

Seeking Alpha · 17 Sept 2026positive

Seeking Alpha highlights Progyny as the US market leader in fertility benefits management, citing robust growth, improving margins, and Q2 2026 results showing 11% revenue growth ex-Amazon with near-100% EPS growth guidance for 2026. The article notes secular tailwinds that position the company for sustained double-digit growth.

Why it matters — PGNY watchers would note the article's emphasis on margin expansion, EPS growth guidance, and sustained market leadership amid growing fertility-benefits demand.

Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know

Zacks Investment Research · 9 Sept 2026positive

Wall Street analysts' mean price target for Progyny (PGNY) points to a roughly 25.2% upside in the stock, according to Zacks Investment Research. The report notes that while price-target metrics have not proven highly effective, strong agreement among analysts in raising earnings estimates suggests upside potential.

Why it matters — PGNY watchers would care because the report highlights analyst confidence in the stock, reflected in both price targets and upward earnings estimate revisions.

Progyny, Inc. to Present at the Wells Fargo Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Progyny, Inc. announced that its Chief Financial Officer, Mark Livingston, will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 8, 2026, at 11:00 a.m. ET.

Why it matters — PGNY watchers would care because the presentation offers an opportunity for the company's CFO to communicate with investors and industry participants at a notable healthcare conference.

Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research highlighted Progyny, Inc. (PGNY) as one of four top-performing liquid stocks, alongside MNDY, MTCH, and WK, noting the companies' strong liquidity, growth attributes, and operational efficiency.

Why it matters — PGNY watchers would care because the company has been singled out by a research outlet as a top liquid stock with strong growth and operational efficiency, reflecting a favorable view of its fundamentals.

FAQ

Frequently asked questions about PGNY stock

What is the PGNY stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Progyny, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PGNY stock a buy right now?

Of the 12 analysts covering Progyny, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Progyny, Inc. 96 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PGNY?

As at 23 Sept 2026, Progyny, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will PGNY stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +34.8% from the last close, and Ticker Nerd's factor model ranks Progyny, Inc. 96 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PGNY stock forecast for 2030?

No analyst covering Progyny, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PGNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.

How has PGNY stock performed over the past year?

Progyny, Inc. returned +19.7% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Progyny, Inc. do?

Progyny Inc is a healthcare benefits management company that provides fertility, family-building, and women’s health solutions for employers. Progyny designs integrated benefit programs that combine clinical expertise, personalized member support, selective provider networks, and pharmacy benefits to help organizations offer specialized reproductive and lifecycle care.

What is the latest news on PGNY?

The most recent item we track (Zacks Investment Research, 18 Sept 2026): "PGNY vs. CRL: Which Stock Is the Better Value Option?". Zacks Investment Research compares Progyny (PGNY) and Charles River Laboratories (CRL) as potential value options within the Medical Services sector. The piece poses the question of which of these two stocks offers investors the better value opportunity at this time.

Company

About Progyny, Inc.

Progyny Inc is a healthcare benefits management company that provides fertility, family-building, and women’s health solutions for employers. Progyny designs integrated benefit programs that combine clinical expertise, personalized member support, selective provider networks, and pharmacy benefits to help organizations offer specialized reproductive and lifecycle care. Its services support areas such as fertility treatment, pregnancy and postpartum care, menopause and midlife support, and benefit navigation for adoption and surrogacy reimbursement. Progyny serves employers across multiple industries that want to include comprehensive family-building and women’s health coverage in their employee benefits packages. The company operates as a focused specialist in employer-sponsored healthcare benefits, playing a distinct role in making complex care pathways easier to manage for members, providers, and benefits administrators.

CEO Mr. Peter Anevski CPA · 835 employees · United States · https://www.progyny.com